ESC: All eyes on Pfizer’s tafamidis as European heart confab kicks off

24th August 2018 Uncategorised 0

Pfizer’s new data on its drug to treat transthyretin cardiomyopathy will likely steal the spotlight at the European Society of Cardiology meeting, but study results from Johnson & Johnson, Bayer, AstraZeneca and Amgen could also draw interest.

More: ESC: All eyes on Pfizer’s tafamidis as European heart confab kicks off
Source: fierce